Fred Moll, M.D
Managing Partner @ Sonder Capital
San Francisco Bay Area, United States
Fred Moll, M.D is a Series A investor at Sonder Capital in San Francisco Bay Area focused on Health Care and Medical Device. Frederic H. Moll, M.D. serves as Chief Development Officer of Johnson & Johnson’s Digital Surgery Group. Prior to Johnson & Johnson, Dr. Moll was CEO of Auris Health, Inc., located in Redwood City, California. Prior to Auris, Dr. Moll founded Hansen Medical and served as the company’s first CEO, and in 1995, founded Intuitive Surgical,Inc. (Nasdaq: ISRG).Dr. Moll earned a M.D. from the University of Washington, School of Medicine, a M.S. degree in Management from Stanford University’s Sloan Program, and a B.A. degree from the University of California at Berkeley.
- Total investments:
- 28
- Last investment:
- Lead investor:
- 18%
Last updated:
For AI agents: llms.txt
Industries Fred Moll, M.D invests in
Stages Fred Moll, M.D invests in
Countries Fred Moll, M.D invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Seed
- $4M–$9.5M
- Series A
- $10M–$31M
- Series B
- $15M–$125M
Investment Focus
Industry
- Health Care 17 (61%)
- Medical Device 15 (54%)
- Medical 6 (21%)
- Robotics 4 (14%)
- Health Diagnostics 3 (11%)
Stage
- Series A 7 (25%)
- Series B 7 (25%)
- Seed 3 (11%)
- Funding Round 3 (11%)
- Series C 2 (7%)
Country
- United States 15 (54%)
- China 1 (4%)
- France 1 (4%)
- Israel 1 (4%)
- United Kingdom 1 (4%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| XCath, meanwhile, is developing steerable robotic microcatheters for treating endovascular conditions such as cerebral strokes. Devices such as these are expected to help treat patients remotely, especially in parts of the world where special surgical procedures are not readily available. | $30M / Series C / Mar 12, 2026 | ||
| Vitestro transform patient care with autonomous blood drawing technology. | $70M / Series B / Mar 10, 2026 | ||
| Petal Surgical is a healthcare platform that intends to make surgery accessible and incisionless. | $10M / Series A / Oct 20, 2025 | ||
| ForSight Robotics develops a surgical robotic platform to deliver high precision and cost-effective vision-saving surgery. | $125M / Series B / Jun 24, 2025 | ||
| G.I. Windows is a clinical-stage company developing the first fundamental breakthrough in surgical anastomotic technology. This technology will allow less invasive surgery and offer the capability of developing more procedures new to the world. The company is creating a new category in healthcare designed to create less invasive surgery and reducehealthcare costs.G.I. Windows is committed to innovation that helps improve the way diagnostic and interventional procedures impact the essential balance between both patients and the healthcare system. It was founded in 2012 and is headquartered in West Bridgewater, Massachusetts, United States. | $37M / Series B / Nov 20, 2024 | ||
| Mendaera is a medtech startup that focuses on developing advanced healthcare technologies, particularly in robotics and diagnostic tools. Mendaera envisions digitizing clinical judgment and technical expertise to ensure that high-quality care is accessible to every patient, in every care facility. Their platform, currently in development,integrates robotics, AI, real-time imaging, and connectivity to enable medical interventions at scale. | $73M / Series B / Sep 26, 2024 | ||
| Vitestro transform patient care with autonomous blood drawing technology. | $21.3M / Series A / Apr 30, 2024 | ||
| The time to resolve critical, significant unmet medical needs in neurosurgery is now. PrimaNova sets sight on resolving unmet medical needs by tackling life-threatening neuro conditions. As an innovator, leveraging decades of experiences in overcoming clinical challenges, harnessing capital, and succeeding to deliver clinical solutions thatfundamentally change treatment paradigms. Collaborating closely with leading neurosurgeons, we are dedicated to offering products that save lives and redefine the standard of care. | Series A / Apr 29, 2024 | ||
| Neuro42 is developing and commercializing advanced MRI and robotics technology for diagnosis and image-guided interventions. | Oct 05, 2023 | ||
| Promaxo is a medical technology company that develops and commercializes customer-centric MRI systems, and MRI compatible robotics and machine learning based technologies that enhance patients' lives and redefine the standard of care. Using proprietary technologies protected by 55+ patents, the Company is bringing the first MRI and roboticsguidance system for in-office use. Products in the pipeline include disposables and an AI-based tissue characterization system. | Oct 04, 2023 | ||
| See all 28 investments → | |||
Co-Investors
About Sonder Capital
Sonder Capital invests in teams and technologies that can transform healthcare in the medical device, diagnostic and healthtech sectors. We are Foundational Investors – we commit our energy and capital early to guide and support companies from inception to acquisition or IPO. We look for big ideas that will change lives.
Sonder Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Andy McGibbon
Managing Partner
|
|||
Jay Watkins
Managing Partner
|
|||
Colby Wood
Managing Partner
|
|||
|
Fred Moll, M.D
Managing Partner
|
|||
Kate Garrett
Managing Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Fred Moll, M.D invest in?
Fred Moll, M.D invests primarily in Health Care, Medical Device and Medical startups, most often at Series A and Series B stage. Most of the 28 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Fred Moll, M.D's check size?
Fred Moll, M.D typically joins rounds of $4M–$9.5M at Seed, $10M–$31M at Series A and $15M–$125M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Fred Moll, M.D participates in.
How do I contact Fred Moll, M.D?
Public channels for Fred Moll, M.D include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Fred Moll, M.D last invest?
The most recent investment recorded for Fred Moll, M.D closed in Mar 2026. Shizune tracks 28 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
